Eptifibatide

Generic Name: Eptifibatide

Brand Names: Integrilin, Eptifibatide Accord

Drug Type: Biotech

Chemical Formula: -

CAS Number: 188627-80-7

Unique Ingredient Identifier: NA8320J834

Background: Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.

Indication: For treatment of myocardial infarction and acute coronary syndrome.

Associated Conditions: Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI)

Associated Therapies: -

Clinical Trials

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Phase 1

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Eptifibatide
Drug: Placebo

First Posted Date: 2009-02-03

Last Posted Date: 2013-06-27

Lead Sponsor: University of North Carolina, Chapel Hill

Target Recruit Count: 13

Registration Number: NCT00834899

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

Phase 2

Terminated

Conditions: ST-Elevation Myocardial Infarction

Interventions: Drug: normal saline
Drug: eptifibatide

First Posted Date: 2008-07-22

Last Posted Date: 2012-08-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 31

Registration Number: NCT00719914

Locations: 🇺🇸
Mid Ohio Heart Clinic, Mansfield, Ohio, United States
🇺🇸
Crittenton Hospital Medical Center, Rochester, Michigan, United States
🇺🇸
Cardiology Research Associates, Ormond Beach, Florida, United States

INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial

Phase 3

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: placebo
Drug: eptifibatide

First Posted Date: 2008-03-19

Last Posted Date: 2010-05-28

Lead Sponsor: Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS

Target Recruit Count: 91

Registration Number: NCT00638976

Locations: 🇮🇹
Mediolanum Cardio Research, Milan, Italy

Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Phase 3

Completed

Conditions: Infarction, Myocardial

Interventions: Drug: Abciximab
Drug: Eptifibatide

First Posted Date: 2007-01-25

Last Posted Date: 2012-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 429

Registration Number: NCT00426751

Locations: 🇩🇪
GSK Investigational Site, Homburg, Saarland, Germany

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

Phase 2

Completed

Conditions: Coronary Disease

Interventions: Drug: Otamixaban (XRP0673)
Drug: unfractionated heparin
Drug: eptifibatide

First Posted Date: 2006-04-24

Last Posted Date: 2014-12-03

Lead Sponsor: Sanofi

Target Recruit Count: 3241

Registration Number: NCT00317395

Locations: 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

Phase 4

Terminated

Conditions: Angioplasty

First Posted Date: 2006-02-10

Last Posted Date: 2007-07-20

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 1200

Registration Number: NCT00289601

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

Phase 1

Completed

Conditions: Stroke

First Posted Date: 2005-11-09

Last Posted Date: 2009-05-08

Lead Sponsor: University of Cincinnati

Target Recruit Count: 94

Registration Number: NCT00250991

Locations: 🇺🇸
University of California, Los Angeles, UCLA Medical Center, 10833 Le Conte Ave., Los Angeles, California, United States
🇺🇸
University of Pennsylvania, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, Pennsylvania, United States
🇺🇸
Mercy Hospital, Western Hills, 3131 Queen City Ave., Cincinnati, Ohio, United States

and more 16 locations

BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Phase 4

Completed

Conditions: Coronary Artery Disease
Myocardial Infarction

Interventions: Drug: eptifibatide

First Posted Date: 2005-05-24

Last Posted Date: 2013-11-28

Lead Sponsor: Cardiology Research UBC

Target Recruit Count: 624

Registration Number: NCT00111566

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Aspirin
Drug: tinzaparin sodium
Drug: eptifibatide

First Posted Date: 2003-05-26

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 18

Registration Number: NCT00061373

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Suburban Hospital, Bethesda, Maryland, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy